Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non-small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
AZD-3759;Erlotinib;Gefitinib
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non-small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. ### Output: AZD-3759;Erlotinib;Gefitinib